Target intelligence / Profile preview

Lipopolysaccharide-induced tumor necrosis factor-alpha factor (LITAF)

Target
LITAF
Molecular classification
Monotopic integral membrane protein (not a classical receptor or enzyme), Zinc-binding protein (contains zinc finger domain), Endosome/lysosome localizing protein involved in multivesicular body (MVB) trafficking and ESCRT accessory function
01

Overview

Lipopolysaccharide-induced tumor necrosis factor-alpha factor (LITAF; also called SIMPLE or PIG7) is a **monotopic zinc-binding integral membrane protein** localized primarily to the **endosomal and lysosomal compartments**. It contains a conserved C-terminal domain (the LITAF or SIMPLE-like domain), responsible for membrane integration via a hydrophobic region stabilized by adjacent zinc finger motifs[1][4]. Its N-terminal PPXY motifs enable protein-protein interactions, especially with components of the ESCRT machinery (such as TSG101 and Nedd4), promoting multivesicular body sorting and lysosomal degradation of membrane proteins[1][3][4][5][6]. LITAF is upregulated by microbial products (notably LPS) and p53, and participates in immune responses by regulating pro-inflammatory cytokines like TNF-α, among others[2][3][6]. Mutations in the LITAF gene cause the demyelinating neuropathy Charcot-Marie-Tooth disease type 1C, and altered expression is associated with cancer, obesity, and inflammatory diseases[1][6]. While considered a potential therapeutic target, there are currently no drugs directly acting on LITAF. Further research continues to elucidate its roles in endosomal trafficking, immune regulation, and disease pathology[1][2][3][4][6].

Other names
SIMPLE (Small integral membrane protein of lysosome/late endosome)PIG7 (p53-induced gene 7 protein)TP53I7 (tumor protein p53 inducible protein 7)Small integral membrane protein of the late endosomeSmall integral membrane protein of lysosome/late endosomeFLJ38636Lipopolysaccharide-induced TNF-alpha factorLPS-induced TNF-alpha factor
02

Mechanism of action

Not well-defined due to lack of directly interacting drugs. In theoretical or research settings, mechanisms would likely involve modulation of cytokine expression, protein trafficking, or autophagy through affecting LITAF's molecular function. Potential future approaches: small molecules or biologics targeting its interaction domains (PPXY motifs, zinc finger), its expression, or downstream signaling

03

Biological functions

Endosomal protein trafficking and lysosomal degradationRegulation of cytokine expression, including TNF-α, CCL2, CCL5, CXCL1, IL1A, IL10Immune response, especially response to lipopolysaccharide (LPS) and pathogensRegulation of autophagyParticipation in downregulation of EGF receptor signalingPotential role in lipid metabolism and cellular signalingPossible regulation of gene expression (nuclear localization has been observed, with DNA binding activity)
04

Disease associations

Charcot-Marie-Tooth disease (CMT) type 1C: Mutations cause autosomal-dominant demyelinating neuropathyCancer: Overexpressed in some cancers, associated with tumor growth and metastasisInflammatory diseases: Implicated due to role in cytokine expression and immune responsesObesity and inflammatory bowel diseases: Altered expression linked to these diseasesPotential role in neurodegenerative disorders (through autophagy regulation)
05

Safety considerations

Therapeutic challenges include lack of specific small-molecule inhibitors and complex involvement in essential protein trafficking and immune functions, which may imply risks of off-target effects or interference with crucial cell processesDisease mutations can cause dominant gain-of-function or interference with membrane-protein trafficking, suggesting any therapeutic targeting must consider potential for toxicity or exacerbation of neuropathy
06

Interacting drugs

No directly approved or established drugs that specifically target LITAF are reported in the current literature. Research is ongoing, especially pertaining to its role in cancer and inflammation
07

Biomarkers

LITAF expression levels (especially upregulation in certain cancers, CMT1C diagnosis, autoimmune/inflammatory conditions)Co-expression with interacting partners (TSG101, Nedd4, Itch), and downstream cytokines (TNF-α, etc.)

Beyond the preview

Go deeper on Lipopolysaccharide-induced tumor necrosis factor-alpha factor (LITAF).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lipopolysaccharide-induced tumor necrosis factor-alpha factor (LITAF).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call